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inTroDucTion
External beam radiotherapy (EBRT) is widely used as 
primary treatment for localized prostate cancer (PCa).1 A 
recent randomized study with a median 10 years follow-up 
demonstrated that, in localized low and intermediate risk 
PCa, EBRT achieves results similar to radical prostatectomy 
in terms of tumor control and disease specific mortality.2 In 
recent years, the development of modern techniques such 
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objective: To evaluate high-precision external beam reir-
radiation (re-EBRT) for local relapse of prostate cancer 
(PCa) after radiotherapy.
Methods: This retrospective study included patients with 
biochemical failure and evidence of isolated local recur-
rence of PCa after radical/salvage EBRT or brachytherapy 
that received salvage stereotactic body radiation 
therapy (SBRT, re-EBRT). Biopsy was not mandatory if 
all diagnostic elements were univocal (prostate specific 
antigen evolution, choline-positron emission tomog-
raphy or magnetic resonance imaging). Salvage SBRT 
(re-EBRT) was delivered with image-guided radiation 
therapy (RapidArc®, VERO® and CyberKnife®).
results: Data of 64 patients were included, median 
age at salvage SBRT was 73.2 years, median pre-sal-
vage SBRT prostate specific antigen was 3.89  ng ml−1 . 
Median total dose was 30  Gy in five fractions, biolog-
ically effective dose (BED) of 150  Gy. One acute G3 
genitourinary event and one late G3 genitourinary event 
were observed. No G ≥ 3 bowel toxicity was registered. 
At the median follow-up of 26.1 months, tumor progres-
sion was observed in 41 patients (64%). 18 patients 
(28%) experienced local relapse. 2-year local control, 
biochemical and clinical relapse free survival rates were 
75, 40 and 53%, respectively. With BED ≥130  Gy 1-year 
biochemical and clinical progression-free survival rate 
were 85 and 90%, respectively.
conclusions: Salvage SBRT (re-EBRT) for isolated 
local PCa recurrence is a safe, feasible and noninvasive 
salvage treatment. Further investigation is warranted to 
define the optimal patient selection, dose and volume 
parameters.
advances in knowledge: Salvage SBRT reirradiation 
for the locally recurrent PCa offer a satisfactory tumor 
control and excellent toxicity profile, if BED ≥130 Gy is 
administered.
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as intensity modulated radiation therapy (IMRT), image-guided 
radiation therapy (IGRT) and stereotactic body irradiation 
(SBRT), in addition to the progressive escalation of the prescribed 
dose, resulted in good tumor local control and enhanced overall 
survival in patients affected by localized PCa.3,4 However, still 
approximately 22–69% of patients develop biochemical failure 
after radical EBRT or radical prostatectomy.5,6
Currently, the standard treatment for locally recurrent PCa is 
not uniquely defined7,8 and different therapeutic options are 
available, including systemic therapy, i.e. androgen depriva-
tion therapy (ADT), or local salvage approaches with curative 
intent, such as salvage prostatectomy, re-irradiation, cryotherapy 
and high intensity focused ultrasound (HIFU). The majority of 
the patient series is small and includes heterogeneous patients 
and treatments without a long follow-up. No randomized trials 
comparing salvage local and systemic strategies are available.7,9,10 
The most effective local therapy has not been established yet 
and remains controversial in the absence of consensus.11–13 
At present, patients with biochemical failure mainly receive 
longlasting ADT with negative impact on the quality of life and 
other health aspects. In selected patients with prostate specific 
antigen (PSA) <10 ng ml−1 and a good life expectancy (>10 
years) a local treatment with radical intent can be considered.7,12
As far as reirradiation is concerned, the vast majority of patient 
series were treated with brachytherapy (BRT). In the last years, 
along with the improvement in radiotherapy (RT) planning and 
delivery technology, several reports on salvage EBRT have been 
published14–27 (Table 1).
Our Division, equipped with high precision RT systems, has a 
long experience of reirradiation.19,28–30 Our reports include 
numerous primary tumor sites, and the majority of studies 
are focused on the recurrent PCa.14,15,19,28–34 In particular, the 
preliminary retrospective analysis published by Zerini et al14 
with a mean follow-up of 21.3 months, reported good local 
tumor control and low toxicity profile in a series of 32 patients 
treated with IG-IMRT for isolated local recurrence of PCa. The 
aim of the current study was to present the outcome in the larger 
patient series treated with salvage SBRT (re-EBRT), including 
updated information of some patients from Zerini's series.14
MeThoDS anD MaTerialS
Study protocol
Inclusion criteria for this retrospective study were: (1) isolated 
local recurrence of PCa after primary EBRT, BRT or salvage 
post-prostatectomy RT; (2) salvage with SBRT (re-EBRT) at the 
European Institute of Oncology between November 2009 and 
November 2016; (3) written informed consent for radiation 
treatment; (4) written informed consent for use of anonymized 
clinical and imaging data for research and education purpose; (5) 
minimum follow-up of 3 months; (6) no evidence of metastatic 
disease. No other local salvage treatment for the recurrent PCa 
was permitted.
This study is a part of the research notified to the Ethical 
Committee of the European Institute of Oncology (notification 
Nr 79: clinical and dosimetric aspects of IGRT for PCa). Data 
of some patients were shared with the French Genito-Urinary 
Group (GETUG) and a separate analysis will be performed. The 
GETUG analysis will regard exclusively the cases with biop-
sy-proven intraprostatic recurrence” (unpublished data).
Biochemical failure
Biochemical failure after the primary therapy was defined as 
two consecutive risings in PSA level >0.2 ng ml−1 post-radical 
prostatectomy and PSA nadir +2 ng ml−1 above the nadir after 
primary RT, according to the Radiation Therapy Oncology 
Group (RTOG) and American Society for Radiation Oncology 
(ASTRO) Phoenix Consensus.35
The diagnosis of local recurrence was based on the biochemical 
failure confirmed by imaging studies, i.e. [11C]-choline positron 
emission tomography with co-registered CT (PET/CT), whole 
body MRI (WB-MRI) including multiparametric MRI (mpMRI) 
of the prostate, whole body CT scan. Choline-PET/CT and 
MRI were used after the diagnosis of biochemical recurrence to 
confirm local recurrence and choline PET/CT was also used to 
exclude nodal and bone metastasis.36–40 Biopsy was not manda-
tory41 if all diagnostic elements were univocal (PSA evolution 
stating for biochemical recurrence, [11C]-choline-PET/CT or 
MRI findings). All cases were discussed in the multidisciplinary 
uro-oncology tumor board.
Treatment procedures
Salvage SBRT (re-EBRT), was delivered with IGRT, employing 
CyberKnife® (Accuray, Inc., Sunnyvale, CA), Vero® (Mitsubishi 
Heavy Industries, Ltd., Japan and BrainLab AG, Feldkirchen, 
Germany) or RapidArc® (Varian Medical Systems, Palo Alto, CA) 
systems whose technical characteristics have been published else-
where.14 Patients treated with CyberKnife had fiducial markers 
implanted into the target. All patients were asked to empty the 
bowel (oral and written instructions for diet and enema were 
given) and to have full urinary bladder for simulation CT and 
all treatment fractions. Gross tumor volume (GTV) contouring 
was based on the mpMRI and PET/CT co-registration. Clinical 
target volume (CTV) included the whole prostate or intrapros-
tatic lesion or prostate bed recurrence with margins. The CTV to 
planning target volume (PTV) margins were 5 mm in all direc-
tions except for the posterior margin where 3 mm margin was 
added. For CyberKnife treatments and in case of short interval 
between two RT courses, comorbidity or unfavorable anatomy 
or dose volume histograms (DVH) data, margins were reduced 
of 1 mm. This decision was supported by the steep dose gradient 
that could be achieved with CyberKnife and intra fraction organ 
motion control performed in all CyberKnife treatments. The 
organs at risk (OARs) included rectum (and its posterior part), 
urinary bladder, penile bulb, penis, testis, femoral heads, peri-
toneal cavity and cauda equina. Dose–volume constraints were: 
Dose given to 30% of rectal volume <13.5 Gy; Dose given to 60% 
of rectal volume <6.7 Gy; Dose given to 30% of urinary bladder 
volume <10.6 Gy (based on our previous series data reported by 
Jereczek-Fossa et al).19 Extreme hypofractionated schedules were 
employed and the fractions were delivered on alternating days. 
Before every fraction image guided procedures were performed 
3 of 14 birpublications.org/bjr Br J Radiol;91:20180494
BJRFull paper: Salvage reirradiation for local recurrent prostate cancer with SBRT
Ta
b
le
 1
. P
ub
lis
he
d
 c
lin
ic
al
 s
er
ie
s 
in
cl
ud
in
g
 p
at
ie
nt
s 
tr
ea
te
d
 w
it
h 
ex
te
rn
al
 b
ea
m
 r
ei
rr
ad
ia
ti
o
n 
fo
r 
lo
ca
lly
 r
ec
ur
re
nt
 p
ro
st
at
e 
ca
nc
er
>
.>
Au
th
or
, 
ye
ar
 o
f 
pu
bl
ic
at
io
n 
[R
ef
]
N
In
iti
al
 
tr
ea
tm
en
t 
m
od
al
ity
M
ed
ia
n 
re
la
ps
e 
tim
e 
(r
an
ge
)
Tr
ea
te
d 
vo
lu
m
e
RT
 
te
ch
ni
qu
e
To
ta
l 
D
os
e a
nd
 
fr
ac
tio
na
tio
n
A
D
T
M
ed
ia
n 
fo
llo
w-
up
 
(r
an
ge
)
To
xi
ci
ty
Lo
ca
l c
on
tr
ol
/ 
pa
tte
rn
 o
f 
fa
ilu
re
O
ve
ra
ll 
su
rv
iv
al
Ka
la
pu
ra
ka
l, 
20
03
24
13
G
ro
up
 A
:
EB
RT
 ±
 A
D
T:
 
8 
pt
s
G
ro
up
 B
:
A
D
T 
: 4
 p
ts
pr
os
ta
te
ct
om
y 
+ 
or
ch
ie
ct
om
y:
 1
N
ot
 re
po
rt
ed
PT
V:
 G
TV
 +
 1
–2
 
cm
3D
-C
RT
 +
 
hy
pe
rt
he
rm
ia
M
ed
ia
n 
to
ta
l d
os
e 
39
.6
 G
y/
 2
2 
fr
(p
rio
r R
T)
M
ed
ia
n 
to
ta
l d
os
e 
66
.6
 (5
9.
4–
70
.2
) f
r 
(n
o 
pr
io
r R
T)
N
eo
ad
ju
va
nt
: 
1 
pt
s
G
ro
up
 A
:
14
 (4
–4
8)
 
m
on
th
s
G
ro
up
 B
:
15
 (6
–3
2)
 
m
on
th
s
Ac
ut
e:
G
ra
de
 4
: 1
 G
I
La
te
G
ra
de
 1
: 3
 G
I, 
1 
G
U
G
ra
de
 2
: 1
 G
I
G
ra
de
 4
: 2
 G
U
G
ro
up
 A
:
M
ed
ia
n 
du
ra
tio
n 
of
 C
R/
PR
: 1
2 
(4
-
27
) m
on
th
s
G
ro
up
 B
M
ed
ia
n 
du
ra
tio
n 
of
 C
R/
PR
: 1
5 
(2
-
32
) m
on
th
s
N
.A
.
Va
va
ss
or
i,
20
10
15
6
EB
RT
N
ot
 re
po
rt
ed
W
ho
le
 g
la
nd
SB
RT
30
 G
y/
 5
 fr
N
eo
ad
ju
va
nt
: 
4 
pt
s
11
.2
 (9
.6
–
18
.6
) m
on
th
s
Ac
ut
e:
G
ra
de
 >
 2
: 
0 
pt
s
La
te
G
ra
de
 >
 2
: 
0 
pt
s
M
ed
ia
n 
tim
e 
to
 cl
in
ic
al
 
pr
og
re
ss
io
n:
 9
.9
 
(9
.2
–1
0)
 m
on
th
s (
1 
re
gi
on
al
, 2
 d
ist
an
t)
11
.2
 
m
on
th
s O
S:
 
10
0%
Je
re
cz
ek
-F
os
sa
,
20
12
19
34
 p
ts/
38
 
le
sio
ns
EB
RT
 ±
 A
D
T:
 
20
 p
ts
Ra
di
ca
l 
pr
os
ta
te
ct
om
y 
±R
T 
± 
A
D
T:
 
14
 p
ts
66
 (2
4–
18
0)
 
m
on
th
s
Lo
ca
l r
ec
ur
re
nc
e 
(1
5 
pt
s)
A
na
sto
m
os
is 
re
cu
rr
en
ce
 (4
 p
ts)
Ly
m
ph
 n
od
e 
re
cu
rr
en
ce
 (1
6 
le
sio
ns
)
M
et
as
ta
sis
 (3
 
le
sio
n)
SB
RT
Lo
ca
l r
ec
ur
re
nc
e
M
ed
ia
n 
to
ta
l d
os
e 
30
 G
y/
4.
5 
fr
An
as
to
m
os
is 
re
cu
rr
en
ce
M
ed
ia
n 
to
ta
l d
os
e 
30
 G
y/
5 
fr
C
on
co
m
ita
nt
, 
5 
pt
s
C
on
co
m
ita
nt
, 
2 
pt
s
9.
5 
(3
–2
8.
9)
 
m
on
th
s
23
 (3
.9
–3
0.
6)
 
m
on
th
s
Lo
ca
l a
nd
 
an
as
to
m
os
is 
re
cu
rr
en
ce
Ac
ut
e:
G
ra
de
 1
: 3
 G
U,
 
1 
G
I
G
ra
de
 2
: 2
 G
U
G
ra
de
 3
: 1
 G
U
La
te
:
G
ra
de
 1
: 1
 G
U
G
ra
de
 2
: 1
 G
U,
 
1 
G
I
G
ra
de
 3
: 1
 G
U
30
 m
on
th
s P
FS
 
(%
) (
95
%
 C
I)
: 2
2.
2 
(0
–5
8.
2)
M
ed
ia
n 
PF
S 
(%
) 
(9
5%
 C
I)
:: 
13
 (1
0,
 
> 
30
)
30
 m
on
th
s P
FS
 
(%
) (
95
%
 C
I)
 : 
33
.0
 
(0
–6
8.
7)
M
ed
ia
n 
PF
S 
(%
) 
(9
5%
 C
I)
: 1
4 
(1
0,
 
> 
30
)
N
ot
 
re
po
rt
ed
Ze
rin
i,
20
15
14
32
EB
RT
 ±
 A
D
T:
 
10
 p
ts
Ra
di
ca
l 
pr
os
ta
te
ct
om
y 
±R
T 
± 
A
D
T 
: 
22
 p
ts
99
.7
 
(2
3–
20
8.
4)
 
m
on
th
s
W
ho
le
 g
la
nd
 (2
2 
pt
s)
Pr
os
ta
te
 b
ed
 (1
0 
pt
s)
SB
RT
M
ed
ia
n 
to
ta
l d
os
e 
25
 G
y/
 m
ed
ia
n 
do
se
/fr
 5
 G
y 
(if
 
no
 p
rio
r s
ur
ge
ry
); 
m
ed
ia
n 
to
ta
l d
os
e 
25
 G
y/
 5
 fr
 (i
f p
rio
r 
su
rg
er
y)
C
on
co
m
ita
nt
, 
11
 p
ts
21
.3
 (2
–5
3)
 
m
on
th
s
Ac
ut
e:
G
ra
de
 1
: 6
 G
U,
 
2 
G
I
G
ra
de
 2
: 2
 G
U,
 
1 
G
I
La
te
:
G
ra
de
 1
: 6
 G
U
G
ra
de
 2
: 1
 G
U
M
ed
ia
n 
tim
e 
to
 b
io
ch
em
ic
al
 
pr
og
re
ss
io
n:
 9
.4
 
(4
.9
–2
7.
8)
 m
on
th
s
M
ed
ia
n 
tim
e 
to
 cl
in
ic
al
 
pr
og
re
ss
io
n:
 1
3.
2 
(2
–5
3)
 m
on
th
s (
4 
lo
ca
l, 
1 
re
gi
on
al
, 7
 
m
et
as
ta
tic
)
21
.3
 
m
on
th
s 
ca
nc
er
-
sp
ec
ifi
c O
S:
 
93
.7
%
Fu
lle
r, 
20
15
16
29
EB
RT
88
 (3
2–
20
0)
 
m
on
th
s
W
ho
le
 g
la
nd
SB
RT
34
 G
y/
5 
fr
N
o
24
 (3
–6
0)
 
m
on
th
s
La
te
G
ra
de
 2
: 3
G
ra
de
 3
: 1
G
ra
de
 4
: 1
Ac
tu
ar
ia
l 2
 y
ea
r 
BF
FS
: 8
2%
2 
ye
ar
 D
FS
: 1
00
%
2 
ye
ar
 O
S:
 
10
0%
A
rc
an
ge
li,
 2
01
52
5
1
Ra
di
ca
l 
pr
os
ta
te
ct
om
y 
+R
T
42
 m
on
th
s
PT
V:
 C
TV
 +
 5
 m
m
SB
RT
30
 G
y/
5 
fr
N
o
6 
m
on
th
s
Ac
ut
e:
G
ra
de
 1
 G
U,
La
te
:
G
ra
de
 0
6 
m
on
th
s L
C:
 
10
0%
6 
m
on
th
s B
FF
S:
 
10
0%
6 
m
on
th
s: 
10
0%
(C
o
nt
in
ue
d
)
4 of 14 birpublications.org/bjr Br J Radiol;91:20180494
BJR  Jereczek-Fossa et al
Au
th
or
, 
ye
ar
 o
f 
pu
bl
ic
at
io
n 
[R
ef
]
N
In
iti
al
 
tr
ea
tm
en
t 
m
od
al
ity
M
ed
ia
n 
re
la
ps
e 
tim
e 
(r
an
ge
)
Tr
ea
te
d 
vo
lu
m
e
RT
 
te
ch
ni
qu
e
To
ta
l 
D
os
e a
nd
 
fr
ac
tio
na
tio
n
A
D
T
M
ed
ia
n 
fo
llo
w-
up
 
(r
an
ge
)
To
xi
ci
ty
Lo
ca
l c
on
tr
ol
/ 
pa
tte
rn
 o
f 
fa
ilu
re
O
ve
ra
ll 
su
rv
iv
al
Le
e, 
20
15
27
2
EB
RT
Ca
se
1:
 1
02
 
m
on
th
s
Ca
se
 2
: 3
5 
m
on
th
s
W
ho
le
 g
la
nd
IM
RT
Ca
se
 1
: 6
6 
G
y/
30
 fr
Ca
se
 2
: 6
9 
G
y/
30
 fr
no
Ca
se
 1
: n
ot
 
re
po
rt
ed
Ca
se
 2
: 4
 
ye
ar
s
Ac
ut
e:
G
ra
de
 >
 3
: 0
,
La
te
:
G
ra
de
 >
 3
: 0
N
ot
 re
po
rt
ed
N
ot
 
re
po
rt
ed
Zi
lli
, 2
01
62
2
14
EB
RT
: 1
2 
pt
s
Pr
im
ar
y 
EB
RT
 
±B
RT
 b
oo
st:
 
2 
pt
s
4.
4 
(2
.3
–7
.4
) 
ye
ar
s
W
ho
le
 g
la
nd
3D
-C
RT
 (1
0 
pt
s)
IM
RT
 (4
 p
ts)
 
bo
os
t B
RT
 
(1
0 
pt
s)
 b
oo
t 
EB
RT
 (3
 p
ts)
M
ed
ia
n 
no
rm
al
iz
ed
 
do
se
 in
 2
 G
y 
fr
: 
85
.1
 (7
0–
93
.4
) G
y, 
α/
β:
 1
.5
 G
y
12
 m
on
th
s 
(m
ed
ia
n 
tim
e)
 
A
D
T:
 1
2 
pt
s
94
 (4
8–
17
2)
 
m
on
th
s
Ac
ut
e:
G
ra
de
 1
: 4
 G
U,
 
6 
G
I G
ra
de
 2
: 
3 
G
U,
 2
 G
I
La
te
G
ra
de
 1
: 3
 G
U,
 
1 
G
I
G
ra
de
 2
: 3
 G
U,
 
3 
G
I
G
ra
de
 3
: 4
 G
U,
 
4 
G
I
G
ra
de
 4
: 4
 G
U,
 
5 
G
I
5 
ye
ar
 B
FF
S:
 
35
.7
±1
2.
8%
5 
ye
ar
 L
RF
S:
 
50
.0
±1
3.
4%
5 
ye
ar
 D
M
FS
: 
85
.7
±9
.4
%
5 
ye
ar
 
ca
nc
er
-
sp
ec
ifi
c 
su
rv
iv
al
: 
10
0%
Ru
te
nb
er
g,
 2
01
62
1
11
Pr
os
ta
te
 B
RT
49
.2
 
(1
2.
9–
13
5.
5)
 
m
on
th
s
W
ho
le
 p
elv
is:
 8
 p
ts
Pr
os
ta
te
 +
pr
ox
im
al
 
SV
s: 
1
Pr
os
ta
te
 o
nl
y:
 2
3D
-C
RT
 (2
 
pt
s)
, I
M
RT
 (9
 
pt
s)
;
m
ed
ia
n 
to
ta
l d
os
e: 
70
.2
 (6
4.
8–
75
.6
) G
y
6 
m
on
th
s 
A
D
T:
 3
 p
ts
2 
ye
ar
 A
D
T:
 
2 
pt
s
26
.5
(1
–5
3.
6)
 
m
on
th
s
Ac
ut
e:
G
2:
 1
La
te
:
G
ra
de
 2
: 2
G
ra
de
 3
: 2
Ac
tu
ar
ia
l 3
 y
ea
r 
BF
FS
: 6
9%
M
ed
ia
n 
tim
e t
o 
lo
ca
l r
el
ap
se
: 1
7.
7 
m
on
th
s (
4 
pt
s)
Ac
tu
ar
ia
l 
3 
ye
ar
 O
S:
 
77
%
Ja
no
ra
y, 
20
16
17
21
Ra
di
ca
l 
pr
os
ta
te
ct
om
y 
+R
T:
 1
0 
pt
s
Pr
im
ar
y 
RT
 
on
ly
: 1
1 
pt
s
11
1 
(3
8–
39
8)
 
m
on
th
s
CT
V:
 G
TV
 +
 1
 o
r 
2 
m
m
 p
er
 D
’A
m
ic
o 
ris
k 
str
at
ifi
ca
tio
n 
(lo
w
/in
te
rm
ed
ia
te
 
vs
 h
ig
h)
SB
RT
36
.2
5 
G
y/
5 
fr
 to
 
th
e 8
0%
 is
od
os
e 
lin
e (
95
%
 P
TV
 
co
ve
ra
ge
)
C
on
co
m
ita
nt
 
(2
 p
ts)
11
.7
 (2
.5
–
46
.5
) m
on
th
s
Ac
ut
e
G
ra
de
 2
: 1
1 
ye
ar
 B
FF
S:
 8
3.
3%
1 
ye
ar
 L
R:
 9
5.
2%
 (1
 
pt
, i
n 
fie
ld
)
11
.7
 
m
on
th
s O
S:
 
10
0%
D
et
ti,
 2
01
61
8
16
Ra
di
ca
l 
pr
os
ta
te
ct
om
y:
 
8 
pt
s
Ra
di
ca
l 
pr
os
ta
te
ct
om
y 
+R
T:
 8
 p
ts
10
.5
 (3
.5
–
21
.4
) y
ea
rs
Pr
os
ta
tic
 b
ed
SB
RT
30
 G
y/
5 
fr
 (i
f 
pr
ev
io
us
 R
T)
;
35
 G
y/
5 
fr
 (i
f n
o 
pr
ev
io
us
 R
T)
Ad
ju
va
nt
 (5
 
pt
s)
10
 (2
–2
1)
 
m
on
th
s
Ac
ut
e: 
G
ra
de
 
1:
 1
La
te
:
G
2:
1
Bi
oc
he
m
ic
al
 
re
sp
on
se
: 1
5 
pt
s
M
ed
ia
n 
tim
e t
o 
re
la
ps
e: 
9.
3 
m
on
th
s 
(7
, d
ist
an
t r
el
ap
se
)
10
 m
on
th
s 
O
S:
 1
00
%
Le
ro
y, 
20
17
20
23
EB
RT
: 1
9 
pt
s
BR
T:
 4
 p
ts
65
 (2
8–
15
0)
 
m
on
th
s
W
ho
le
 g
la
nd
: 1
9
Fo
ca
l: 
3
H
em
i-p
ro
sta
te
: 1
SB
RT
36
 G
y 
to
 th
e 8
0%
 
iso
do
se
 li
ne
 (9
5%
 
PT
V
 co
ve
ra
ge
)
C
on
co
m
ita
nt
 
(1
4 
pt
s)
22
 (6
–4
0)
 
m
on
th
s
Ti
m
e o
f o
ns
et
: 
no
t r
ep
or
te
d
G
ra
de
 1
: 1
3
G
ra
de
 2
: 9
G
ra
de
 3
: 3
G
ra
de
 4
: 0
2 
ye
ar
 D
FS
: 5
4%
20
 m
on
th
s D
FS
: 
60
.9
%
 (5
 lo
ca
l, 
1 
no
da
l a
nd
 
3 
m
et
as
ta
tic
 
re
cu
rr
en
ce
s)
2 
ye
ar
 O
S:
 
10
0%
Ta
b
le
 1
. (
C
o
nt
in
ue
d
)
(C
o
nt
in
ue
d
)
5 of 14 birpublications.org/bjr Br J Radiol;91:20180494
BJRFull paper: Salvage reirradiation for local recurrent prostate cancer with SBRT
Au
th
or
, 
ye
ar
 o
f 
pu
bl
ic
at
io
n 
[R
ef
]
N
In
iti
al
 
tr
ea
tm
en
t 
m
od
al
ity
M
ed
ia
n 
re
la
ps
e 
tim
e 
(r
an
ge
)
Tr
ea
te
d 
vo
lu
m
e
RT
 
te
ch
ni
qu
e
To
ta
l 
D
os
e a
nd
 
fr
ac
tio
na
tio
n
A
D
T
M
ed
ia
n 
fo
llo
w-
up
 
(r
an
ge
)
To
xi
ci
ty
Lo
ca
l c
on
tr
ol
/ 
pa
tte
rn
 o
f 
fa
ilu
re
O
ve
ra
ll 
su
rv
iv
al
M
be
ut
ch
a, 
20
17
26
28
H
D
RB
: 1
6 
pt
s
EB
RT
: 1
2 
pt
s
69
 m
on
th
s 
(I
Q
R:
 5
5–
85
)
49
 m
on
th
s 
(I
Q
R:
 3
7–
70
)
PT
V:
 C
TV
 +
 1
 m
m
BR
T 
(1
0 
pt
s)
,
SB
RT
 (1
8 
pt
s)
35
 G
y/
5 
fr
35
 G
y/
5 
fr
C
on
co
m
ita
nt
 
(2
 p
ts)
C
on
co
m
ita
nt
 
(1
0 
pt
s)
22
.5
 m
on
th
s 
(I
Q
R:
 8
–4
2)
14
.5
 m
on
th
s 
(I
Q
R:
 7
–2
3)
Ac
ut
e:
G
ra
de
 1
: 2
 G
U,
 
1 
G
I
G
ra
de
 2
: 7
 G
U
La
te
:
G
ra
de
 1
: 1
 G
I
G
ra
de
 2
: 6
 G
U
 
G
ra
de
3:
 1
 G
U
Ac
ut
e:
G
ra
de
 1
: 5
 G
U,
 
1 
G
I
G
ra
de
 2
: 2
 G
U,
 
2 
G
I
La
te
:
G
ra
de
1:
4 
G
U
G
ra
de
 2
: 1
 G
U,
 
1 
G
I
G
ra
de
 4
: 1
 G
U
BR
T:
Bi
oc
he
m
ic
al
 
re
cu
rr
en
ce
 fr
ee
 
su
rv
iv
al
: 4
4.
4%
 at
 
19
.5
 m
on
th
s (
IQ
R:
 
14
–3
6)
SB
RT
:
Bi
oc
he
m
ic
al
 
re
cu
rr
en
ce
 fr
ee
 
su
rv
iv
al
: 3
3.
3%
 at
 
7 
m
on
th
s (
IQ
R:
 
4–
7)
N
.A
.
Lo
i, 
20
18
23
50
Po
st-
pr
os
ta
te
ct
om
y 
RT
: 2
2 
pt
s
Ra
di
ca
l E
BR
T:
 
26
 p
ts
76
 (9
–2
05
) 
m
on
th
s
W
ho
le
 g
la
nd
,
D
IL
SB
RT
30
 G
y 
to
 th
e 8
0%
 
iso
do
se
 li
ne
 (9
5%
 
PT
V
 co
ve
ra
ge
)
C
on
co
m
ita
nt
 
(1
1 
pt
s)
21
.3
 (6
.1
–
49
.2
)
Ac
ut
e:
G
ra
de
 1
: 9
 G
U,
 
4 
G
I
G
ra
de
 2
: 1
 G
U
G
ra
de
 3
: 1
 G
U
La
te
:
G
ra
de
 1
: 9
 G
U,
 
1 
G
I
G
ra
de
 2
: 3
 G
U,
 
2 
G
I
G
ra
de
 3
: 1
 G
U,
 
1 
G
I
1 
ye
ar
 B
FF
S:
 8
0%
1 
ye
ar
 D
M
FS
: 9
2%
N
.A
.
Cu
rr
en
t s
tu
dy
64
a
Po
st-
pr
os
ta
te
ct
om
y 
RT
: 1
9 
pt
s
Ra
di
ca
l E
BR
T:
 
40
 p
ts
Ra
di
ca
l B
RT
: 
4 
pt
s
Ra
di
ca
l E
BR
T 
+ 
BR
T:
 1
 p
ts
99
.7
 
(2
3–
20
8.
4)
 
m
on
th
s
PP
I: 
4
W
ho
le
 g
la
nd
: 4
0
W
ho
le
 g
la
nd
 
+D
IL
: 1
Pr
os
ta
te
 b
ed
 
re
cu
rr
en
ce
: 1
9
IM
RT
 (5
0 
pt
s)
SB
RT
 (1
4p
ts)
M
ed
ia
n 
to
ta
l d
os
e 
30
 G
y/
 6
 fr
, M
ed
ia
n 
do
se
/fr
ac
tio
n 
6 
G
y 
(3
–1
2)
.
M
ed
ia
n 
nu
m
be
r o
f 
fr
ac
tio
ns
 5
 (2
–1
0)
C
on
co
m
ita
nt
 
(1
6 
pt
s)
26
.1
 (3
.1
–
82
.4
) m
on
th
s
Ac
ut
e:
G
ra
de
 2
: 3
 G
U,
 
1 
G
I
G
ra
de
 3
: 1
 G
U
La
te
:
G
ra
de
 2
: 6
 G
U,
 
1 
G
I
G
ra
de
 3
: 1
 G
U
2 
ye
ar
 L
C:
 7
5%
2 
ye
ar
 B
FF
S:
 4
0%
2 
ye
ar
 C
lin
ic
al
 fr
ee
 
su
rv
iv
al
: 5
3%
2 
ye
ar
 O
S:
 
92
%
.
2 
ye
ar
 
PC
SS
: 9
5%
3D
-C
R
T,
 3
 d
im
en
si
o
na
l-
co
nf
o
rm
al
 r
ad
ia
ti
o
n 
th
er
ap
y;
 A
D
T,
 a
nd
ro
g
en
 d
ep
ri
va
ti
o
n 
th
er
ap
y;
 B
F
F
S
, 
b
io
ch
em
ic
al
 f
ai
lu
re
 f
re
e 
su
rv
iv
al
; 
B
R
T,
 b
ra
ch
yt
he
ra
p
y;
 C
R
/P
R
, 
co
m
p
le
te
 r
es
p
o
ns
e/
p
ar
ti
al
 r
es
p
o
ns
e;
 C
T
V
, 
cl
in
ic
al
 t
ar
g
et
 v
o
lu
m
e;
 D
F
S
, 
d
is
ea
se
-f
re
e 
su
rv
iv
al
; 
D
IL
, 
d
o
m
in
an
t 
in
tr
ap
ro
st
ic
 l
es
io
n;
 D
M
F
S
, 
d
is
ta
nt
 m
et
as
ta
se
s 
fr
ee
 s
ur
vi
va
l; 
E
B
R
T,
 e
xt
er
na
l 
b
ea
m
 r
ad
ia
ti
o
n 
th
er
ap
y;
 f
r, 
fr
ac
ti
o
n;
 G
T
V
, 
g
ro
ss
 t
um
o
r 
vo
lu
m
e;
 
G
T
V
G
I, 
g
as
tr
o
in
te
st
in
al
; G
U
, g
en
it
o
ur
in
ar
y;
 IM
R
T,
 in
te
ns
it
y 
m
o
d
ul
at
ed
 r
ad
ia
ti
o
n 
th
er
ap
y;
 L
C
, l
o
ca
l c
o
nt
ro
l; 
N
.A
, n
o
t 
av
ai
la
b
le
; O
S
, o
ve
ra
ll 
su
rv
iv
al
; P
C
S
S
, p
ro
st
at
e 
ca
nc
er
 s
p
ec
ifi
c 
su
rv
iv
al
; P
P
I, 
p
ar
ti
al
 p
ro
st
at
e 
ir
ra
d
ia
ti
o
n;
 p
t,
 p
at
ie
nt
; R
T,
 r
ad
ia
ti
o
n 
th
er
ap
y;
 S
B
R
T,
 s
te
re
o
ta
ct
ic
 r
ad
ia
ti
o
n 
th
er
ap
y;
a
27
 p
ts
 f
ro
m
 Z
er
in
i e
t 
al
14
 w
it
h 
up
-d
at
ed
 f
o
llo
w
-u
p
.
Ta
b
le
 1
. (
C
o
nt
in
ue
d
)
6 of 14 birpublications.org/bjr Br J Radiol;91:20180494
BJR  Jereczek-Fossa et al
(with cone beam CT in Vero and Rapidarc patients) or intrafrac-
tion control was used (CyberKnife). Additionally, automated 
infrared marker-based patient-positioning device integrated into 
the Vero system was employed (ExacTrac, BrainLab AG Feld-
kirchen, Germany).The patients received premedication with 
dexamethasone and α-blockers.
Outcome assessment
Acute and chronic toxicity was registered by a radiation oncolo-
gist according to the RTOG/European Organization for Research 
and Treatment of Cancer Guideline (RTOG/EORTC) during 
salvage SBRT (re-EBRT), and subsequently every 6–12 months 
after the end of salvage SBRT (re-EBRT) . Gastrointestinal (GI) 
and genitourinary (GU) events were registered whereas sexual 
dysfunction was not analysed here due to lack of baseline eval-
uation. Serum PSA level was tested every 3 months until any 
biochemical or clinical progression. In patients with a reduction 
or stabilization of PSA levels at follow-up, non-additional radio-
logical or nuclear medicine evaluation was requested.
Likewise, the primary treatment, biochemical failure after 
reirradiation was defined as PSA nadir +2 ng ml−1 (Phoenix 
consensus).35 In post-prostatectomy patients, biochemical 
progression was defined as a continuous increase in PSA over the 
pre-re-EBRT value confirmed by at least two tests.14 In case of 
local relapse, the data were censored for toxicity in order to avoid 
the misinterpretation of local symptoms of relapse as GI and GU 
events. Biochemical progression-free survival was measured as 
the time from the beginning of salvage SBRT (re-EBRT) to the 
PSA increase after salvage SBRT (re-EBRT). Clinical progres-
sion-free survival was measured as the time from the beginning 
of re-EBRT to the radiological detection of local progression or 
distant disease. LC was measured from the beginning of salvage 
SBRT (re-EBRT) and the radiological diagnosis of in-field 
relapse.
In patients treated by ADT and salvage SBRT (re-EBRT), the 
PSA value before the start of ADT was considered as pre-salvage 
SBRT (re-EBRT) PSA level. The prescribed dose of reirradiation 
was converted to biologically effective dose (BED) calculated 
using an α/β ratio 1.5 Gy.
STaTiSTical analySiS
Patient and tumor characteristics were represented as frequen-
cies and percentages when classified with categorical variables 
and with median values and range for continuous variables.42 
The correlation between treatment doses and clinical outcome 
were investigated with Cox proportional-hazards regression. 
Survival analysis was performed with Kaplan–Meier approach, 
and differences between groups were evaluated with log-rank 
test.43 A p-value < 0.05 was considered significant.
reSulTS
Patient data
Between November 2009 and November 2016, 73 patients with 
biochemical failure and evidence of isolated local relapse of PCa 
after radical/salvage EBRT or BRT were treated with salvage 
SBRT (re-EBRT) in our department. For this retrospective 
analysis, 64 patients were eligible according the inclusion 
criteria. Nine patients were excluded due to metastatic disease 
at the time of reirradiation and one patient was excluded for 
the reirradiation technique (three-dimensional conformal 
radiotherapy, 3D-CRT). 27 out of 32 patients included in Zeri-
ni's series14 fulfilled the criteria of the current study and their 
updated follow-up data have been included here. The median 
follow-up for the whole series was 26.1 months (range 3.1–82.4 
months).
Patient and tumor characteristics
Patient and tumor characteristics are listed in Table  2. Local 
relapse was documented by [11C]-choline PET/CT, pelvic MRI, 
and total body CT scan in 53 (83%), 40 (63%) and 4 (6%) patients, 
respectively. Biopsy of the radiologically documented recurrent 
lesion was performed in 28 patients (44%). For the remaining 
41 patients (non-biopsied or non-positive at biopsies), diag-
nosis of isolated local recurrence of prostate cancer was based 
on PSA levels (stating for biochemical recurrence) and radiolog-
ical confirmation with PET, CT scan and/or MRI. All cases were 
discussed with the multidisciplinary uro-oncology tumor board 
and the clinical decision was taken jointly.
Previous EBRT included 3D-CRT in 55 patients (median dose: 
70.2 Gy), IMRT in 4 patients (median dose: 66.1 Gy) and 4 
patients received low dose rate interstitial BRT (median dose: 145 
Gy). At the first EBRT, the most of the patients were treated with 
a conventional fractionation, and 9 patients received moderate 
hypofractionation.
Treatment
Salvage SBRT (re-EBRT) was performed for intraprostatic recur-
rence and for post-prostatectomy bed recurrence in 45 (70%) 
and 19 (30%) cases, respectively. CTV of reirradiation included 
the whole prostate in 40 patients (63%), mpMRI-identified intra-
prostatic relapse (partial prostate reirradiation) in 4 patients 
(6%), whole prostate and simultaneous boost to intraprostatic 
relapse in 1 patient (1%) and prostatic surgical bed nodule in 19 
patients (30%). The schedules used for salvage SBRT (re-EBRT)
are presented in the Table 3.
Extreme hypofractionation was employed in the majority of 
patients. Median dose was 30 Gy (range: 20–30 Gy) given in five 
fractions (range: 2–10). The choice of the schedule was based on 
the clinical situation (age, comorbidity, time interval between 
two RT courses ìetc.) and was at the physician discretion. In three 
patients, hypofractionated SBRT was employed due to important 
comorbidity
Patients treated with a total salvage SBRT (re-EBRT) BED <130 
Gy had major comorbidities (i.e. ischemic cardiopathy, previous 
percutaneous transluminal coronary angioplasty), previous 
abdominal surgery and antiplatelet/anticoagulant therapy.
Concomitant ADT included luteinizing hormone-releasing 
hormone agonist (LHRHa), antiandrogens and combined 
androgen blockade (CAB) in 8, 4 and 4 patients, respectively.
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Table 2. Patient characteristics (N = 64 patients)
Characteristics All patients, n = 64 Prostate, n = 45 Prostate bed, n = 19
PRIOR RT
Initial PSA [ng ml–1], median (range) 11.4 (0.5–228.5) 11.69 (3.4–228.5) 16.7 (0.5–110)
Initial Gleason Score, median (range) 7 (2–9) 6 (4–8) 7 (2–9)
Prior RT modality
  3D 55 38 17
  3D + BRT 1 1
  BRT 4 4
  IMRT 4 2 2
Dose (Gy), median (range) 70.2 (45–145) 75 (50–145) 70 (45–77.4)
Interval between first RT and re–EBRT [months], median  
(range)
99.7 (23–208.4) 102.6 (23–208.4) 93.9 (27.9–183.3)
Re–EBRT
Age at re–EBRT [years], median (range) 73.2 (52.6–81.7) 65.2 (47–81.7) 59.4 (48.8–70.5)
Pre re–EBRT PSA [ng/ml], median (range) 3.89 (0.17–51.8) 4.29 (0.24–21) 3 (0.17–51.8)
Androgen deprivation
  Yes (%) 16 (25%) 10 6
  No (%) 48 (75%) 35 13
  Duration [months], median (range) 17.8 (3.0–38.1) 14.7 (7.6–37.9) 20.6 (3.0–38.1)
Biopsy of the target lesion
  Yes (%) 28 (44%) 21 7
  Positive 23 18 5
  Gleason scorea (range) 7 (6–9) 7 (6–9)
  No (%) 36 (56%) 24 12
Histological +/–Radiological diagnosis
  Biopsy + PET + MRI 11
  Biopsy + MRI 6
  Biopsy + PET 11
  MRI + PET 15
  PET only 12
  PET+CT+MRI 3
  PET+CT 1
  MRI only 5
Target lesion
  Prostate 45 (70%) 45 (70%)
  PPI 4 40 4 40
  Whole gland 1 1
  Whole gland+ Intraprostatic relapse 19 (30%) 19 (30%)
  Prostate bed recurrence
Total dose [Gy], median (range) 30 (20–30) 30 (20–30) 25 (25–30)
Dose/fraction [Gy], median (range) 6 (3–12) 6 (3–12) 5 (5–6)
(Continued)
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Tumor outcome
At the median follow-up of 26.1 months from salvage SBRT 
(re-EBRT) (range: 3.1–82.4 months), progressive disease was 
observed in 41 patients (64%) (Table  4). In all cases, clinical 
progression followed biochemical progression. 18 patients 
(28%) experienced clinically/radiologically evident local 
relapse. Median time to progression was 14 months (range: 
3.1–65.9 months), which was similar in both groups, namely 
13.8 months (range 3.4–51.8) for prostate-bed subgroup and 14 
months (range 3.1–65.3) for prostate subgroup. Patients irradi-
ated at prostate-bed appear to have higher proportion of clinical 
relapse, whether patients treated on prostate presented a higher 
proportion of biochemical recurrence only. However, differences 
between groups were not statistically significant at χ2 test (we 
added these results in Table 4).
The 2 year actuarial biochemical progression-free survival and 
clinical progression free survival rates were 40 and 53%, respec-
tively. Local control at 2 years was 75%. Overall survival and PCa 
specific survival rates at 2 years were 92 and 95%, respectively. 
Five patients with a second clinical and biochemical relapse 
underwent a new re-EBRT.44 At the last follow-up, 59 patients 
were alive. 23 (36%) patients showed no evidence of disease, 35 
patients (44%) were alive with biochemical or clinical disease 
and 1 was lost to follow-up. Five patients (8%) died: three for 
disease progression, one for another type of tumor and one of 
unknown cause.
Considering salvage SBRT (re-EBRT)BED (≥130 Gy vs <130), 
statistically significant differences were found for the 1-year 
biochemical progression-free survival rate (85 vs 60%, p-value 
= 0.0006) and 1-year clinical progression-free survival rate 
(90 vs 73%, p-value = 0.0026), as shown in the Kaplan–Meier 
curves (Figure  1). No statistically significant differences 
between patients treated with a total BED <130 Gy or ≥130 Gy 
were found for local control at 2 years (85% vs 65%, p-value 
= 0.09) and overall survival at 2 years (95% vs 90%, p-value = 
0.38).
For patients treated with addition of ADT and without ADT, 
biochemical progression was observed in 12/16 patients (75%) 
and in 25/48 (52%) patients, respectively.
Considering salvage SBRT (re-EBRT) setting (prostate in place 
and post-prostatectomy tumor bed), tumor progression was 
observed in 27/45 patients (60%) and 14/19 (74%) patients, 
respectively.
Toxicity
Acute toxicity was assessed in 64 patients (Table 5). Considering 
the maximum grade of toxicity observed at the end or during the 
first 6 months after salvage SBRT (re-EBRT), 46 patients (72%) 
had no acute toxicity. One patient experienced acute Grade 3 GU 
event represented by transitory macroscopic hematuria.
Late toxicity was evaluated in 62 patients (Table 5). One patient 
experienced late Grade 3 GU event represented by permanent 
reduction in urinary bladder capacity. Late toxicity was missing 
for two patients (follow-up <6 months). No patient developed 
Grade 4 or 5 toxicity.
To evaluate long-term toxicity in our series, we reviewed the 
data of the patients with follow-up longer than 36 months. 
In 20 patients monitored for more than 36 months after 
salvage SBRT (re-EBRT (31% of our series), only 1 Grade 
3 GU event was registered (reduction in urinary bladder 
capacity).
Characteristics All patients, n = 64 Prostate, n = 45 Prostate bed, n = 19
Number of fractions, median (range) 5 (2–10) 5 (2–10) 5
3D, three-dimensional conformal RT; BRT, brachytherapy; CT, whole body computer tomography; PPI, partial prostate 
irradiation; PET, [11C]-choline positron emission tomography with co-registered computed tomography; PPI, partial 
prostateirradiation; PSA, prostate specificantigen; re-EBRT, external beam re-irradiation; RT, radiotherapy; IMRT, 
intensity modulated radiation therapy;
aavailable in 10 patients
Table 2. (Continued)
Table 3. Treatment schedules
Total dose [Gy]
(Dose/fraction [Gy] × num. fractions)
30  
(3 × 10)
25
(5 × 5)
30  
(5 × 6)
30  
(6 × 5)
20  
(10 × 2)
24  
(12 × 2)
BED [Gy] (α/β = 1.5 Gy) 90 108.3 130 150 153.3 216
LINAC Total (%) Number of patients
CyberKnife® 3 (5%) – 1 – – 1 1
VERO® 54 (84%) 3 18 1 28 – –
Trilogy® (RAPIDARC) 7 (11%) – 8 – 3 – –
BED: biologically effective doseIMRT, intensity modulated radiation therapy;
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No significant difference was observed between the groups with 
regard to acute toxicity. As concerning late toxicity, Grade 2 
genitourinary events appear to be more frequent in patients who 
received reirradiation to prostate bed (5 events out of 19 patients 
in prostate-bed subgroup against 1 event out of 45 patients in 
prostate subgroup, p-value = 0.002, χ2 test).
DiScuSSion
To the best of our knowledge, this is the largest series on the 
salvage SBRT (re-EBRT) of isolated local PCa recurrence. Our 
study including 64 patients showed that local salvage SBRT 
(re-EBRT) is safe and offers promising tumor control. Indeed, 
only one patient experienced late Grade 3 toxicity and almost 
half of the patients were free of progression and in conse-
quence free of new therapies at 2 years after salvage SBRT 
(re-EBRT).
Our excellent rates of GU and GI side effects confirm the good 
profile of toxicity reported also by other investigators in smaller 
series.17,18,20,21,23,25 For example, Leroy et al20 in a series of 23 
patients treated with SBRT (36 Gy in 6 fractions) did not observe 
Grade 4 or 5 toxicity. Importantly, in our series no patient expe-
rienced urinary incontinence, a typical complication of other 
salvage local therapies. Urinary incontinence has been observed 
in a range of 35–65% for patients treated with salvage prostatec-
tomy, 10–40% with HIFU, 10.4% with BRT and 3–19% with cryo-
therapy.7,9,45,46 Salvage SBRT (re-EBRT), might be considered a 
valid tool in the armamentarium of local salvage approaches. Its 
noninvasive character represents a particular benefit in patients 
with contraindications to more invasive therapies, like surgery, 
cryoablation, HIFU or even BRT (advanced age, medical condi-
tions including coagulopathy, severe obesity, anesthesia contra-
indications  etc.). two- dimensional
The efficacy of salvage reirradiation for locally recurrent PCa 
has been evaluated by several investigations.14–19,22–26,28–34 
The first report on re-EBRT by Vavassori et al15 including six 
cases treated by CyberKnife, showed the feasibility of reirradi-
ation with an acceptable rate of acute and early chronic toxicity 
(median follow-up was 11.3 months). These preliminary find-
ings were then confirmed by the successive series.14,16–19,28–34 All 
but one report concluded that salvage re-EBRT is safe.14–21,23–27 
Zilli et al22 published the data of 14 patients treated with whole 
prostate reirradiation, with the median follow-up of 94 months, 
showing low acute but very high late GU and GI toxicity rates 
(29% of patients experienced combined Grade 4 GU/GI injury). 
Contrarily to the Zilli’s series, we observed only 1 Grade 3 GU 
event among 20 males with follow-up >36 months. This huge 
difference between observed toxicity profiles most probably 
results from differences in re-EBRT techniques. All our patients 
received salvage SBRT whereas in the report of Zilli et al. 71% of 
patients were retreated with 3D-CRT BRT boost. Moreover, the 
first RT course in the Zilli’s series included two-dimensional irra-
diation in 30% of patients, probably with important exposure of 
rectum and urinary bladder to high doses. These findings under-
line the absolute necessity to use the best available techniques 
and extremely careful planning when reirradiation is considered. 
In our practice, we employ the dosimetric constraints based 
on the OAR doses in the first patients treated with CyberKnife 
re-EBRT for isolated local recurrence. 19
Table 4. Patterns of failure evaluated on 41 patients
Outcome All patients (%) Prostate Prostate bed p-value
Biochemical relapse only 11 (27%) 9 (33%) 2 (14%) 0.19
Whole gland 8
PPI 1
Concomitant ADT 3 2 1
Clinical recurrence IN-FIELDa 13 (32%) 8 (30%) 5 (36%) 0.69
Concomitant ADT 5 3 2
Clinical recurrence IN-FIELD and OUT-FIELDb 5 (12%) 2 (7%) 3 (21%) 0.19
Concomitant ADT 2 0 2
Clinical recurrence OUT-FIELDa 12 (29%) 8 (29%) 4 (29%) 0.94
Locoregional relapse with metastatic relapse 2 (5%) 1 (4%) 1 (7%) .62
Concomitant ADT 0 0 0
Locoregional relapse 5 (12%) 5 (18%) 0 –
Concomitant ADT 1 1 0
Metastatic relapse 5 (12%) 2 (7%) 3 (21%) 0.19
Concomitant ADT 1 1 0
TOTAL 41 27 14
ADT: Androgen deprivation therapy PPI: partial prostate irradiation
Medianfollow-up was 26.1 months. Statisticalanalysis is performed with χ2 test.
aAnd biochemical relapse
bWith biochemical relapse and metastatic relapse out-field
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The satisfactory toxicity profile in our series opens the question 
of dose escalation. Indeed, we observed a statistically significant 
difference for the biochemical progression free survival and clin-
ical progression-free survival, as shown in the Kaplan–Meier 
curves. Since toxicity our series was very low despite the inclu-
sion of numerous patients with comorbidities, we do believe that 
BED >130 Gy should be considered in all patients undergoing 
salvage SBRT (re-EBRT). Higher doses were employed by some 
investigators15,17,20,21,23,24,26 still maintaining acceptable toxicity 
level and somehow higher tumor control when compared to our 
findings. We do believe that these somehow suboptimal tumor 
control might be explained both by inclusion of patients with 
aggressive disease (high PSA and Gleason score at the first diag-
nosis and at the diagnosis of recurrent cancer) and relatively 
low doses prescribed in our series. For example, in the series 
presented by Loi et al, 1-year biochemical relapse-free survival 
was 80%, comparable with 85% 1-year biochemical progression 
free survival rate in our series when BED ≥130 Gy was adminis-
tered. Nonetheless, we have to considered that most our patients 
received a relatively low dose at the first course of RT (median 
dose of 70.2 Gy), while for patients recently treated in the dose 
escalation era with higher BED at first treatment, the safe dose 
of re-EBRT still have to be defined, especially for the risk of late 
rectal toxicity.47
The benefit of combined use of ADT in salvage local RT is not 
clear. Two recent randomized trials showed a progression-free 
survival and/or overall survival improvement when LHRHa 
or bicalutamide was added to salvage post-prostatectomy RT 
(the benefit was greater in case of more aggressive tumors and 
higher pre-salvage RT PSA).48,49 However, no data are available 
for combined ADT and RT in the re-EBRT setting.10,45,50 In our 
series, concomitant ADT was prescribed in 16 (25%) patients, 
this percentage being lower than in other series.20,46 Whenever 
possible, exclusive local therapy was proposed, reserving ADT for 
future tumor progression. Ideally, local therapy should minimize 
the burden of systemic therapies and their side effects. Interest-
ingly, lower tumor control was observed in patients treated with 
concomitant ADT, and this can be at least partially explained by 
the selection of patients in whom ADT was added to re-EBRT 
(i.e. high initial PSA, initial castration resistance etc.). Several 
questions, including addition of ADT and treated volume, must 
still be answered in local salvage therapy of PCa. A consensus 
on the salvage BRT has been recently published in order to help 
clinicians managing intraprostatic recurrence.13 Consensus for 
salvage EBRT still needs to be undertaken.
concluSion
Salvage SBRT (Re-EBRT), is a safe, feasible and noninva-
sive salvage treatment for the locally recurrent PCa, offering 
Figure 1. (a) b-PFS rate, (b) c-PFS rate, (c)LC, (d) OS by BED <130 Gy (solid line) and BED ≥130 Gy (dashed line). BED,biologically 
effective dose; b-PFS, Biochemical progression free survival rate; c-PFS, Clinical progression free survival rate; LC, local control; 
OS, Overall survival.
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a satisfactory tumor control and excellent toxicity profile, if 
BED ≥130 Gy is administered. Further prospective studies are 
warranted to define the optimal patient selection and establish 
the optimal dose and volume parameters for this particular clin-
ical scenario.
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